192 related articles for article (PubMed ID: 31672856)
21. Evaluation of the liquid biopsy for the detection of BRAFV600E mutation in metastatic melanoma patients.
Salvianti F; Massi D; De Giorgi V; Gori A; Pazzagli M; Pinzani P
Cancer Biomark; 2019; 26(3):271-279. PubMed ID: 31524142
[TBL] [Abstract][Full Text] [Related]
22. Clinical utility of serial analysis of circulating tumour cells for detection of minimal residual disease of metastatic nasopharyngeal carcinoma.
Ko JM; Vardhanabhuti V; Ng WT; Lam KO; Ngan RK; Kwong DL; Lee VH; Lui YH; Yau CC; Kwan CK; Li WS; Yau S; Guo C; Choi SSA; Lei LC; Chan KC; Lam CC; Chan CK; Dai W; Khong PL; Lung ML
Br J Cancer; 2020 Jul; 123(1):114-125. PubMed ID: 32372027
[TBL] [Abstract][Full Text] [Related]
23. Clinical significance of BRAF V600E mutational status in capsular nevi of sentinel lymph nodes in patients with primary cutaneous melanoma.
Siroy AE; Aung PP; Torres-Cabala CA; Tetzlaff MT; Nagarajan P; Milton DR; Curry JL; Ivan D; Prieto VG
Hum Pathol; 2017 Jan; 59():48-54. PubMed ID: 27666765
[TBL] [Abstract][Full Text] [Related]
24. BRAF mutation status is an independent prognostic factor for resected stage IIIB and IIIC melanoma: implications for melanoma staging and adjuvant therapy.
Barbour AP; Tang YH; Armour N; Dutton-Regester K; Krause L; Loffler KA; Lambie D; Burmeister B; Thomas J; Smithers BM; Hayward NK
Eur J Cancer; 2014 Oct; 50(15):2668-76. PubMed ID: 25070294
[TBL] [Abstract][Full Text] [Related]
25. Mutation analysis of BRAF and KIT in circulating melanoma cells at the single cell level.
Sakaizawa K; Goto Y; Kiniwa Y; Uchiyama A; Harada K; Shimada S; Saida T; Ferrone S; Takata M; Uhara H; Okuyama R
Br J Cancer; 2012 Feb; 106(5):939-46. PubMed ID: 22281663
[TBL] [Abstract][Full Text] [Related]
26. Circulating Tumor Cells in Stage IV Melanoma Patients.
Hall CS; Ross M; Bowman Bauldry JB; Upshaw J; Karhade MG; Royal R; Patel S; Lucci A
J Am Coll Surg; 2018 Jul; 227(1):116-124. PubMed ID: 29746918
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib.
Punnoose EA; Atwal S; Liu W; Raja R; Fine BM; Hughes BG; Hicks RJ; Hampton GM; Amler LC; Pirzkall A; Lackner MR
Clin Cancer Res; 2012 Apr; 18(8):2391-401. PubMed ID: 22492982
[TBL] [Abstract][Full Text] [Related]
28. Circulating Melanoma Cell Subpopulations: Their Heterogeneity and Differential Responses to Treatment.
Gray ES; Reid AL; Bowyer S; Calapre L; Siew K; Pearce R; Cowell L; Frank MH; Millward M; Ziman M
J Invest Dermatol; 2015 Aug; 135(8):2040-2048. PubMed ID: 25830652
[TBL] [Abstract][Full Text] [Related]
29. Expanded Genomic Profiling of Circulating Tumor Cells in Metastatic Breast Cancer Patients to Assess Biomarker Status and Biology Over Time (CALGB 40502 and CALGB 40503, Alliance).
Magbanua MJM; Rugo HS; Wolf DM; Hauranieh L; Roy R; Pendyala P; Sosa EV; Scott JH; Lee JS; Pitcher B; Hyslop T; Barry WT; Isakoff SJ; Dickler M; Van't Veer L; Park JW
Clin Cancer Res; 2018 Mar; 24(6):1486-1499. PubMed ID: 29311117
[No Abstract] [Full Text] [Related]
30. Prospective assessment of the prognostic value of circulating tumor cells and their clusters in patients with advanced-stage breast cancer.
Mu Z; Wang C; Ye Z; Austin L; Civan J; Hyslop T; Palazzo JP; Jaslow R; Li B; Myers RE; Jiang J; Xing J; Yang H; Cristofanilli M
Breast Cancer Res Treat; 2015 Dec; 154(3):563-71. PubMed ID: 26573830
[TBL] [Abstract][Full Text] [Related]
31. Association of a novel circulating tumor DNA next-generating sequencing platform with circulating tumor cells (CTCs) and CTC clusters in metastatic breast cancer.
Davis AA; Zhang Q; Gerratana L; Shah AN; Zhan Y; Qiang W; Finkelman BS; Flaum L; Behdad A; Gradishar WJ; Platanias LC; Cristofanilli M
Breast Cancer Res; 2019 Dec; 21(1):137. PubMed ID: 31801599
[TBL] [Abstract][Full Text] [Related]
32. Non-invasive sensitive detection of KRAS and BRAF mutation in circulating tumor cells of colorectal cancer patients.
Mohamed Suhaimi NA; Foong YM; Lee DY; Phyo WM; Cima I; Lee EX; Goh WL; Lim WY; Chia KS; Kong SL; Gong M; Lim B; Hillmer AM; Koh PK; Ying JY; Tan MH
Mol Oncol; 2015 Apr; 9(4):850-60. PubMed ID: 25605225
[TBL] [Abstract][Full Text] [Related]
33. Molecular signatures of circulating melanoma cells for monitoring early response to immune checkpoint therapy.
Hong X; Sullivan RJ; Kalinich M; Kwan TT; Giobbie-Hurder A; Pan S; LiCausi JA; Milner JD; Nieman LT; Wittner BS; Ho U; Chen T; Kapur R; Lawrence DP; Flaherty KT; Sequist LV; Ramaswamy S; Miyamoto DT; Lawrence M; Toner M; Isselbacher KJ; Maheswaran S; Haber DA
Proc Natl Acad Sci U S A; 2018 Mar; 115(10):2467-2472. PubMed ID: 29453278
[TBL] [Abstract][Full Text] [Related]
34. Circulating tumor cells as a response monitor in stage IV non-small cell lung cancer.
Shishido SN; Carlsson A; Nieva J; Bethel K; Hicks JB; Bazhenova L; Kuhn P
J Transl Med; 2019 Aug; 17(1):294. PubMed ID: 31462312
[TBL] [Abstract][Full Text] [Related]
35. Systemic treatments for metastatic cutaneous melanoma.
Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
[TBL] [Abstract][Full Text] [Related]
36. Real-time HER2 status detected on circulating tumor cells predicts different outcomes of anti-HER2 therapy in histologically HER2-positive metastatic breast cancer patients.
Zhang S; Li L; Wang T; Bian L; Hu H; Xu C; Liu B; Liu Y; Cristofanilli M; Jiang Z
BMC Cancer; 2016 Jul; 16():526. PubMed ID: 27456503
[TBL] [Abstract][Full Text] [Related]
37. Detection and Characterization of Circulating Tumor Associated Cells in Metastatic Breast Cancer.
Mu Z; Benali-Furet N; Uzan G; Znaty A; Ye Z; Paolillo C; Wang C; Austin L; Rossi G; Fortina P; Yang H; Cristofanilli M
Int J Mol Sci; 2016 Sep; 17(10):. PubMed ID: 27706044
[TBL] [Abstract][Full Text] [Related]
38. Filtration based assessment of CTCs and CellSearch® based assessment are both powerful predictors of prognosis for metastatic breast cancer patients.
Huebner H; Fasching PA; Gumbrecht W; Jud S; Rauh C; Matzas M; Paulicka P; Friedrich K; Lux MP; Volz B; Gass P; Häberle L; Meier-Stiegen F; Hartkopf A; Neubauer H; Almstedt K; Beckmann MW; Fehm TN; Ruebner M
BMC Cancer; 2018 Feb; 18(1):204. PubMed ID: 29463222
[TBL] [Abstract][Full Text] [Related]
39. Monitoring changes in circulating tumour cells as a prognostic indicator of overall survival and treatment response in patients with metastatic melanoma.
Klinac D; Gray ES; Freeman JB; Reid A; Bowyer S; Millward M; Ziman M
BMC Cancer; 2014 Jun; 14():423. PubMed ID: 24915896
[TBL] [Abstract][Full Text] [Related]
40. Quantitative analysis of the BRAF
Ashida A; Sakaizawa K; Mikoshiba A; Uhara H; Okuyama R
Int J Clin Oncol; 2016 Oct; 21(5):981-988. PubMed ID: 27041702
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]